Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

NICE NG71 recommends that clinicians advise PwP to take a vitamin D supplement and signposted to other NICE guidelines on vitamin D for recommendations on vitamin D testing, and the NICE guidelines on falls in older people and osteoporosis (Table 1). van der Marck et al. placed osteoporosis under generic risk factors for falls in PD providing summary advice regarding the “method of ascertainment” of osteoporosis (including “BMD assessment”), “who should be involved” (general practitioner, geriatrician, clinical pharmacist), and “suggested intervention” (anti‐osteoporotic treatment, physical activity). 46 The BONE‐PARK algorithm was the only guideline identified that provided treatment options available, with particular consideration given to PD‐specific factors.

Source: PD and Bone Health. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Systematic review.

Systematic review

Uses explicit methods to identify, assess and summarise research on a defined question.

Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Management of Osteoporosis in Parkinson's Disease: A Systematic Review of Clinical Practice Guidelines

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Management of Osteoporosis in Parkinson's Disease: A Systematic Review of Clinical Practice Guidelines

Systematic review · Movement Disorders Clinical Practice · 2024

Original publication title

Management of Osteoporosis in Parkinson's Disease: A Systematic Review of Clinical Practice Guidelines

Mícheál Ó Breasail; Karan P. Singh; Fiona E. Lithander; Sze‐Ee Soh; Victor McConvey; Jennifer McGinley; Meg E. Morris; Peter R. Ebeling; Jesse Zanker; Ayse Zengin

© 2025 The Author(s). Movement Disorders Clinical Practice published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

This review highlights that despite the documented high fracture rates of PwP, health professionals do not always have adequate resources to support them when considering how to manage osteoporosis. Osteoporosis screening and management needs to be incorporated into PD treatment guidelines, and equally providing specific recommendations for PwP related to bone health in national osteoporosis guidelines should be a priority given the high burden of fracture in the patient population.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

The aims were to identify and appraise clinical practice guidelines, consensus statements, and treatment algorithms containing recommendations for bone health in people with PD (PwP).

Source: Objectives

Abstract: What methods does the paper describe?

We systematically searched 4 electroninc databases (MEDLINE, Embase, Emcare, and Web of Science) (n = 78), in addition to the websites of organizations, societies, and professional bodies focused on PD or osteoporosis (n = 28), up to April 22, 2024.

Source: Methods

Abstract: Results

After duplicate removal, screening, and full‐text review, 6 records were included. Included records were appraised using the AGREE II (Appraisal of Guidelines for Research and Evaluation) tool. All records recognized bone health as a concern in PD, yet recommendations for fracture‐risk screening were inconsistent. Two of six records grouped PD under the broad category of neurological diseases. The acceptability and tolerance of anti‐osteoporosis medications in PwP was discussed only in 1 record, which incorporated national osteoporosis guidelines into a PD‐specific treatment algorithm.

Source: Results

Abstract: Conclusions

This review highlights that despite the documented high fracture rates of PwP, health professionals do not always have adequate resources to support them when considering how to manage osteoporosis. Osteoporosis screening and management needs to be incorporated into PD treatment guidelines, and equally providing specific recommendations for PwP related to bone health in national osteoporosis guidelines should be a priority given the high burden of fracture in the patient population.

Source: Conclusions
Authors’ abstract

Abstract

Background

Parkinson's disease (PD) is the fastest‐growing neurological disorder globally. Defining features include tremor, muscular rigidity, bradykinesia, and postural instability, which in combination with nonmotor symptoms such as cognitive impairment and orthostatic hypotension increase the risk of falls. Along with low bone mineral density, fracture risk is high in PD.

Objectives

The aims were to identify and appraise clinical practice guidelines, consensus statements, and treatment algorithms containing recommendations for bone health in people with PD (PwP).

Methods

We systematically searched 4 electroninc databases (MEDLINE, Embase, Emcare, and Web of Science) (n = 78), in addition to the websites of organizations, societies, and professional bodies focused on PD or osteoporosis (n = 28), up to April 22, 2024.

Results

After duplicate removal, screening, and full‐text review, 6 records were included. Included records were appraised using the AGREE II (Appraisal of Guidelines for Research and Evaluation) tool. All records recognized bone health as a concern in PD, yet recommendations for fracture‐risk screening were inconsistent. Two of six records grouped PD under the broad category of neurological diseases. The acceptability and tolerance of anti‐osteoporosis medications in PwP was discussed only in 1 record, which incorporated national osteoporosis guidelines into a PD‐specific treatment algorithm.

Conclusions

This review highlights that despite the documented high fracture rates of PwP, health professionals do not always have adequate resources to support them when considering how to manage osteoporosis. Osteoporosis screening and management needs to be incorporated into PD treatment guidelines, and equally providing specific recommendations for PwP related to bone health in national osteoporosis guidelines should be a priority given the high burden of fracture in the patient population.

Publication and source details

Original title: Management of Osteoporosis in Parkinson's Disease: A Systematic Review of Clinical Practice Guidelines

Mícheál Ó Breasail; Karan P. Singh; Fiona E. Lithander; Sze‐Ee Soh; Victor McConvey; Jennifer McGinley; Meg E. Morris; Peter R. Ebeling; Jesse Zanker; Ayse Zengin

Movement Disorders Clinical Practice · 2024

* Correspondence to: Dr. Mícheál Ó Breasail, Department of Medicine, School of Clinical Sciences at Monash Health, Faculty of Medicine, Monash Medical Centre, Nursing and Health Sciences, Monash University, Level 5/Block E, 246 Clayton Road, Clayton, VIC 3168, Australia; E‐mail: micheal.obreasail@monash.edu
© 2025 The Author(s). Movement Disorders Clinical Practice published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T07:49:49.762752+00:00

DOI: 10.1002/mdc3.14311 · PMC11952945